#insurance

11 articles tagged #insurance.

Ready to compare providers? Take the 2-minute match quiz or see the cheapest GLP-1 options.

#2026 4#503a 1#503b 2#FDA 1#alternatives 1#ban 1#before-and-after 1#beginners 2#brand-name 3#bridge-program 1#cagrilintide 1#cagrisema 1#comparison 2#compounded 8#compounded-semaglutide 1#compounded-tirzepatide 1#compounding-ban 1#copay 1#cost 13#coupon 1#coverage 1#diabetes 1#diet 1#dosage 1#eli-lilly 3#enforcement 1#enrollment 1#fact-check 1#fda 3#fda-approval 1#flat-rate 1#foundayo 7#framework 1#glp-1-patches 1#glucose-monitors 1#guide 1#hhs 1#hims 1#how-to-get 1#injectable 7#injection 1#insulin-resistance 1#insurance 11#ivy-rx 1#ivyrx 1#legality 1#liraglutide 1#medicaid 1#medicare 5#mounjaro 6#news 2#novo-nordisk 2#oral-glp1 6#oral-semaglutide 1#orforglipron 4#ozempic 7#pcos 1#pill 1#pipeline 1#policy 1#prior-authorization 2#regulation 2#results 1#rfk 1#ro 1#safety 3#savings-card 1#schedule 1#semaglutide 19#shortage 1#side-effects 9#supplements 1#surmount 2#surmount-5 1#telehealth-enforcement 1#telehealth-review 1#timeline 1#tirzepatide 18#type-2-diabetes 1#warning-letters 1#wegovy 16#wegovy-hd 1#wegovy-pill 3#weight-loss 26#without-insurance 1#zepbound 17
Editorial lifestyle photograph illustrating Medicare Part D GLP-1 coverage in 2026
GuideCost & InsuranceJune 30, 2026• 18 min read

Medicare GLP-1 Coverage July 2026: $50/mo Wegovy + Zepbound Bridge Program Guide

Updated June 30, 2026 (launch day eve): Medicare Part D covers Foundayo, Wegovy, and Zepbound for weight loss starting July 1, 2026 via the Medicare GLP-1 Bridge program. Flat $50/month copay. 3.4 million beneficiaries eligible. Both oral pills (Foundayo and Wegovy tablet) are covered. Runs through Dec 31, 2027 (BALANCE Model Part D launch delayed indefinitely as of April 2026; Bridge extended to fill the gap).

Editorial still-life evoking metabolic balance and women's health, warm natural light
GuideCost & InsuranceJune 24, 2026• 11 min read

GLP-1 for PCOS (2026): Ozempic, Wegovy & Cheaper Compounded Paths

GLP-1 medications like Ozempic and Wegovy can help PCOS because the syndrome is driven by insulin resistance, and these drugs improve insulin sensitivity, drive weight loss, and in trials restored menstrual regularity and raised natural-pregnancy rates. But here is the catch almost no one explains: PCOS by itself is NOT an FDA-approved reason to prescribe any GLP-1, so insurance and brand savings cards hinge on your BMI and comorbidities, not your PCOS diagnosis. This guide covers the trial signal, why insurance denies PCOS-only requests, the BMI rules behind savings cards, and the cheaper cash-pay paths if you do not qualify.

Editorial still-life illustrating the Medicare GLP-1 Bridge enrollment process and access to weight-loss medication
GuideCost & InsuranceJune 11, 2026• 16 min read

Medicare GLP-1 Bridge Enrollment Guide 2026: $50 Copay for Foundayo, Wegovy & Zepbound

Updated June 11, 2026: CMS released the official prior authorization request form (cms.gov/glp-1-bridge.pdf, June 8) revealing a key eligibility nuance, beneficiaries with OSA, MASH, T2D, or established CVD are NOT eligible for the Bridge (they route through regular Part D instead). The Bridge is for weight-management-only patients. Four drugs covered at a $50/month flat copay: Foundayo, Wegovy injection, Wegovy oral tablet, and Zepbound KwikPen. Prior auth via Humana/LI NET; requests not processed before July 1. Complete enrollment guide.

Editorial photograph illustrating a comparison of Zepbound and Mounjaro tirzepatide medications
AnalysisComparisonsApril 22, 2026• 12 min read

Zepbound vs Mounjaro (April 2026): Same Drug, Different Labels, Which Is Right for You?

Verified April 2026: Zepbound and Mounjaro are the exact same drug (tirzepatide) at the same doses. Mounjaro was FDA-approved May 2022 for Type 2 diabetes. Zepbound was FDA-approved November 2023 for chronic weight management and December 2024 for obstructive sleep apnea. List price is ~$1,087/mo for both; with commercial insurance + savings cards both drop to $25/mo (max $1,950/yr). The real differences: which one your insurance covers, what the FDA label allows, and Zepbound's LillyDirect self-pay vials at $299-$449/mo, a program Mounjaro does not offer.

Editorial lifestyle photograph illustrating a 2026 GLP-1 cost guide
AnalysisCost & InsuranceApril 17, 2026• 11 min read

GLP-1 Cost 2026: Wegovy, Zepbound & Ozempic Prices ($25–$1,350/mo)

How much do GLP-1 medications cost in 2026? Wegovy, Zepbound, Ozempic, Mounjaro & Foundayo range from $25–$1,350/month. With insurance + savings card: $25/mo. Without insurance: $146/mo compounded sema (Yucca Health), $149/mo Foundayo pill, $299–449/mo brand injectable (LillyDirect, NovoCare). Medicare: $50/mo starting July 2026. Prices verified April 17, 2026 across 48 providers.

Featured Partners

Four affiliate partners we feature, we may earn a commission.

Yucca Health

7.7/10
$146/mo·Compounded
Visit Yucca HealthReview

Gala

7.2/10
$149/mo·Brand & Compounded
Visit GalaReview

TrimRx

7.8/10
$149/mo·Compounded
Visit TrimRxReview

SkinnyRx

7.3/10
$199/mo·Compounded
Visit SkinnyRxReview

Affiliate links, we earn a commission at no extra cost to you. These are featured partners, prioritized by our affiliate economics, not an editorial "best" ranking. The objective ranking (by methodology score) and full methodology are at glp1picks.com/best.